Some indicators of left ventricular dysfunction in hypertensive patients, depending on the level of matrix metalloproteinases and tissue inhibitors of metalloproteinase-1

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Aim. To study the level of matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinases-1, the indicator of left ventricular myocardial deformation in patients with stage 1–2 hypertension.

Methods. 114 patients (40 women and 74 men) with hypertension of 1–2 stages observed in the cardiology “Department of the Road clinical hospital Chita II” were examined. The median age was 42±8.3 years. Left ventriclular diastolic function was studied by using tissue Doppler imaging in apical four-chamber views. Serum matrix metalloproteinase-1, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinases-1 levels were measured in all patients on automated immunoassay analyzers using ready-to-use ELISA kits.

Results. An increase in serum levels of matrix metalloproteinases-1 and -2 in the group of patients with hypertension and diastolic dysfunction by 46 and 47%, respectively, was found against increased levels of serum tissue inhibitor of metalloproteinase-1 (р=0.049). In patients with diastole dysfunction, myocardial global longitudinal strain was decreased in was observed by 22.8% compared with patients without diastole dysfunction (p <0.05). The analysis revealed a moderate negative relationship between left ventricular global longitudinal strain and the serum levels of metalloproteinases-2 (r=0.64, p <0.05).

Conclusion. In patients with hypertension and left ventricular diastolic dysfunction, a decrease in left ventricular global longitudinal strain is associated with the serum level of matrix metalloproteinase-2; a tissue inhibitor of metalloproteinases-1 is unrelated to left ventricular global myocardial strain.

About the authors

T V Kalinkina

Chita State Medical Academy

Author for correspondence.
Email: kalink-tatyana@yandex.ru
Russian Federation, Chita, Russia

N V Lareva

Chita State Medical Academy

Email: kalink-tatyana@yandex.ru
Russian Federation, Chita, Russia

M V Chistyakova

Chita State Medical Academy

Email: kalink-tatyana@yandex.ru
Russian Federation, Chita, Russia

References

  1. Belenkov Yu.N. Left ventricular remodeling: a comprehensive approach. Russian heart failure journal. 2002; 3 (4): 161–163. (In Russ.)
  2. Razin V.A., Gimaev R.H., Movchan E.V. Myocardial fibrosis and insulin-like growth factor-1 in arterial hypertension, connection with structural and functional changes of the heart. Therapist. 2012; (3): 4–8. (In Russ.)
  3. Yarmolinskaya M.I., Molotkov A.S., Denisova V.M. Matrix metalloproteinases and inhibitors: classification, mechanism of action. Journal of obstetrics and women's diseases. 2012; 61 (1): 113–125. (In Russ.)
  4. Teplyakov A.T., Berezikova E.N., Shilov S.N., Grakova E.V., Torim Yu.Yu., Efremov A.V., Safronov I.D., Pustovetova M.G., Karpov R.S. Assessment of the role of matrix metalloproteinase-2 gene polymorphism in the development of chronic heart failure. Terapevticheskiy arkhiv. 2015; (4): 8–12. (In Russ.) doi: 10.17116/terarkh20158748-12.
  5. Kalinkina T.V., Lareva N.V., Gorbunov V.V., Chistyakova M.V. Gene polymorphisms of the renin-angiotensin-aldosterone system in hypertensive patients in the formation of diastolic dysfunction. Zabaykalskiy meditsinskiy vestnik. 2019; (1): 25–32. (In Russ.)
  6. Kalinkina T.V., Lareva N.V., Chistyakova M.V., Emelyanova O.N. Gene­tic aspects of endothelium dysfunction in hypertensive patients. Zabaykalskiy meditsinskiy vestnik. 2017; (4): 7–11. (In Russ.)
  7. Prosya­nik V.I., Serebryakova O.V., Serkin D.M., Khacheryan M.K., Bakalova Yu.V., Goncharova E.V. Matrix metalloprotei­nases in type 1 diabetic patients with diabetic cardiomyo­pathy. Zabaykalskiy meditsinskiy vestnik. 2019; (4): 97–104. (In Russ.)
  8. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Failure. 2016; 18: 891–975. doi: 10.1002/ejhf.592.
  9. Laviades C., Varo N., Fernandez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998; 98: 535–540. doi: 10.1161/01.CIR.98.6.535.
  10. Marsalskaya O.A., Nikiforov V.S. Longitudinal deformation of the left ventricle and the left atrium in workers of railway transport with arterial hypertension. Systemic Hypertension. 2015; 12 (4): 18–22. (In Russ.) doi: 10.26442/SG29106.
  11. Kalinkina T.V., Lareva N.V., Chistyakova M.V., Gorbunov V.V. The relationship of endotelial dysfunction with the development of diastolic heart failure in patients with hypertension. Rational Pharmacotherapy in Cardiology. 2020; 16 (3): 370–376. (In Russ.) doi: 10.20996/1819-6446-2020-05-04.
  12. Larina V.N. Choice of effective diuretic for congestive heart failure treatment at the outpatient stage: arguments for torasemide use. Consilium medicum. 2018; 20 (10): 29–35. (In Russ.) doi: 10.26442/2075-1753_2018.10.29-35.
  13. DrapkinaO.M., Palatkina L.O. New emphases on the study of the pathogenesis of chronic heart failure with preserved ejection fraction: focus on inflammatory markers. Rational Pharmacotherapy in Cardio­logy. 2014; 10 (3): 317–321. (In Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2021 Eco-Vector





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies